 | • レポートコード：MRC23Q35976 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の子宮内膜症治療薬市場について調査・分析し、世界の子宮内膜症治療薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（ホルモン避妊薬、プロゲステロン補充療法、GnRHAアナログ）、用途別セグメント分析（病院、薬局、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Bayer、Abbott、Ferring、Xianju Pharma、AstraZeneca、Merck & Co、Takeda Pharmaceutical、Theramex、Livzon Pharmaceutical Group、Beijing Biote Pharmaceutical Co., ltdなどが含まれています。世界の子宮内膜症治療薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、子宮内膜症治療薬市場規模を推定する際に考慮しました。本レポートは、子宮内膜症治療薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、子宮内膜症治療薬に関するビジネス上の意思決定に役立てることを目的としています。 ・子宮内膜症治療薬市場の概要 - 子宮内膜症治療薬のタイプ別セグメント - 世界の子宮内膜症治療薬市場規模：タイプ別分析（ホルモン避妊薬、プロゲステロン補充療法、GnRHAアナログ） - 子宮内膜症治療薬の用途別セグメント - 世界の子宮内膜症治療薬市場規模：用途別分析（病院、薬局、その他） - 世界の子宮内膜症治療薬市場規模予測（2018年-2029年） ・子宮内膜症治療薬市場の成長トレンド - 子宮内膜症治療薬の地域別市場規模（2018年-2029年） - 子宮内膜症治療薬市場ダイナミクス - 子宮内膜症治療薬の業界動向 - 子宮内膜症治療薬市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：ホルモン避妊薬、プロゲステロン補充療法、GnRHAアナログ - 世界の子宮内膜症治療薬のタイプ別市場規模（2018年-2023年） - 世界の子宮内膜症治療薬のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、薬局、その他 - 世界の子宮内膜症治療薬の用途別市場規模（2018年-2023年） - 世界の子宮内膜症治療薬の用途別市場規模（2024年-2029年） ・子宮内膜症治療薬の地域別市場規模 - 北米の子宮内膜症治療薬市場規模（2018年-2029年） - アメリカの子宮内膜症治療薬市場規模（2018年-2029年） - ヨーロッパの子宮内膜症治療薬市場規模（2018年-2029年） - アジア太平洋の子宮内膜症治療薬市場規模（2018年-2029年） - 中国の子宮内膜症治療薬市場規模（2018年-2029年） - 日本の子宮内膜症治療薬市場規模（2018年-2029年） - 韓国の子宮内膜症治療薬市場規模（2018年-2029年） - インドの子宮内膜症治療薬市場規模（2018年-2029年） - オーストラリアの子宮内膜症治療薬市場規模（2018年-2029年） - 中南米の子宮内膜症治療薬市場規模（2018年-2029年） - 中東・アフリカの子宮内膜症治療薬市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Bayer、Abbott、Ferring、Xianju Pharma、AstraZeneca、Merck & Co、Takeda Pharmaceutical、Theramex、Livzon Pharmaceutical Group、Beijing Biote Pharmaceutical Co., ltd ・アナリストの観点/結論 ・調査方法とデータソース |
Endometriosis (EMs) is a common gynecological disease in women caused by the implantation of endometrial cells in abnormal locations. Endometrial cells should grow in the uterine cavity, but because the uterine cavity through the fallopian tube and ovary, pelvic cavity is connected, so the endometrial cells can enter the ovary, pelvic cavity and uterus adjacent area through the fallopian tube ectopic growth. It is one of the most common gynecological diseases, but also a relatively common clinical benign disease in women of childbearing age, the disease affects 10% of women of childbearing age, in recent years shows a significant upward trend, the disease is characterized by dysmenorrhea, pelvic pain and infertility, seriously affecting women’s reproductive health and quality of life.
Highlights
The global Endometriosis Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
In China markets, the core manufacturers of endometriosis treatment includes Bayer, Abbott, Ferring etc and the top 5 companies hold a share over 65%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Endometriosis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Endometriosis Treatment.
The Endometriosis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Endometriosis Treatment market comprehensively. Regional market sizes, concerning products by type, by distribution channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Endometriosis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by distribution channel, and by regions.
By Company
Bayer
Abbott
Ferring
Xianju Pharma
AstraZeneca
Merck & Co
Takeda Pharmaceutical
Theramex
Livzon Pharmaceutical Group
Beijing Biote Pharmaceutical Co., ltd
Segment by Type
Hormonal Contraceptives
Progesterone Replacement Therapy
GnRHAnalogue
Segment by Distribution Channel
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, distribution channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Endometriosis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by distribution channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Endometriosis Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Hormonal Contraceptives
1.2.3 Progesterone Replacement Therapy
1.2.4 GnRHAnalogue
1.3 Market by Distribution Channel
1.3.1 Global Endometriosis Treatment Market Growth by Distribution Channel: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Endometriosis Treatment Market Perspective (2018-2029)
2.2 Endometriosis Treatment Growth Trends by Region
2.2.1 Global Endometriosis Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Endometriosis Treatment Historic Market Size by Region (2018-2023)
2.2.3 Endometriosis Treatment Forecasted Market Size by Region (2024-2029)
2.3 Endometriosis Treatment Market Dynamics
2.3.1 Endometriosis Treatment Industry Trends
2.3.2 Endometriosis Treatment Market Drivers
2.3.3 Endometriosis Treatment Market Challenges
2.3.4 Endometriosis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Endometriosis Treatment Players by Revenue
3.1.1 Global Top Endometriosis Treatment Players by Revenue (2018-2023)
3.1.2 Global Endometriosis Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Endometriosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Endometriosis Treatment Revenue
3.4 Global Endometriosis Treatment Market Concentration Ratio
3.4.1 Global Endometriosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Endometriosis Treatment Revenue in 2022
3.5 Endometriosis Treatment Key Players Head office and Area Served
3.6 Key Players Endometriosis Treatment Product Solution and Service
3.7 Date of Enter into Endometriosis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Endometriosis Treatment Breakdown Data by Type
4.1 Global Endometriosis Treatment Historic Market Size by Type (2018-2023)
4.2 Global Endometriosis Treatment Forecasted Market Size by Type (2024-2029)
5 Endometriosis Treatment Breakdown Data by Distribution Channel
5.1 Global Endometriosis Treatment Historic Market Size by Distribution Channel (2018-2023)
5.2 Global Endometriosis Treatment Forecasted Market Size by Distribution Channel (2024-2029)
6 North America
6.1 North America Endometriosis Treatment Market Size (2018-2029)
6.2 North America Endometriosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Endometriosis Treatment Market Size by Country (2018-2023)
6.4 North America Endometriosis Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Endometriosis Treatment Market Size (2018-2029)
7.2 Europe Endometriosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Endometriosis Treatment Market Size by Country (2018-2023)
7.4 Europe Endometriosis Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Endometriosis Treatment Market Size (2018-2029)
8.2 Asia-Pacific Endometriosis Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Endometriosis Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Endometriosis Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Endometriosis Treatment Market Size (2018-2029)
9.2 Latin America Endometriosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Endometriosis Treatment Market Size by Country (2018-2023)
9.4 Latin America Endometriosis Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Endometriosis Treatment Market Size (2018-2029)
10.2 Middle East & Africa Endometriosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Endometriosis Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Endometriosis Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Detail
11.1.2 Bayer Business Overview
11.1.3 Bayer Endometriosis Treatment Introduction
11.1.4 Bayer Revenue in Endometriosis Treatment Business (2018-2023)
11.1.5 Bayer Recent Development
11.2 Abbott
11.2.1 Abbott Company Detail
11.2.2 Abbott Business Overview
11.2.3 Abbott Endometriosis Treatment Introduction
11.2.4 Abbott Revenue in Endometriosis Treatment Business (2018-2023)
11.2.5 Abbott Recent Development
11.3 Ferring
11.3.1 Ferring Company Detail
11.3.2 Ferring Business Overview
11.3.3 Ferring Endometriosis Treatment Introduction
11.3.4 Ferring Revenue in Endometriosis Treatment Business (2018-2023)
11.3.5 Ferring Recent Development
11.4 Xianju Pharma
11.4.1 Xianju Pharma Company Detail
11.4.2 Xianju Pharma Business Overview
11.4.3 Xianju Pharma Endometriosis Treatment Introduction
11.4.4 Xianju Pharma Revenue in Endometriosis Treatment Business (2018-2023)
11.4.5 Xianju Pharma Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Endometriosis Treatment Introduction
11.5.4 AstraZeneca Revenue in Endometriosis Treatment Business (2018-2023)
11.5.5 AstraZeneca Recent Development
11.6 Merck & Co
11.6.1 Merck & Co Company Detail
11.6.2 Merck & Co Business Overview
11.6.3 Merck & Co Endometriosis Treatment Introduction
11.6.4 Merck & Co Revenue in Endometriosis Treatment Business (2018-2023)
11.6.5 Merck & Co Recent Development
11.7 Takeda Pharmaceutical
11.7.1 Takeda Pharmaceutical Company Detail
11.7.2 Takeda Pharmaceutical Business Overview
11.7.3 Takeda Pharmaceutical Endometriosis Treatment Introduction
11.7.4 Takeda Pharmaceutical Revenue in Endometriosis Treatment Business (2018-2023)
11.7.5 Takeda Pharmaceutical Recent Development
11.8 Theramex
11.8.1 Theramex Company Detail
11.8.2 Theramex Business Overview
11.8.3 Theramex Endometriosis Treatment Introduction
11.8.4 Theramex Revenue in Endometriosis Treatment Business (2018-2023)
11.8.5 Theramex Recent Development
11.9 Livzon Pharmaceutical Group
11.9.1 Livzon Pharmaceutical Group Company Detail
11.9.2 Livzon Pharmaceutical Group Business Overview
11.9.3 Livzon Pharmaceutical Group Endometriosis Treatment Introduction
11.9.4 Livzon Pharmaceutical Group Revenue in Endometriosis Treatment Business (2018-2023)
11.9.5 Livzon Pharmaceutical Group Recent Development
11.10 Beijing Biote Pharmaceutical Co., ltd
11.10.1 Beijing Biote Pharmaceutical Co., ltd Company Detail
11.10.2 Beijing Biote Pharmaceutical Co., ltd Business Overview
11.10.3 Beijing Biote Pharmaceutical Co., ltd Endometriosis Treatment Introduction
11.10.4 Beijing Biote Pharmaceutical Co., ltd Revenue in Endometriosis Treatment Business (2018-2023)
11.10.5 Beijing Biote Pharmaceutical Co., ltd Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details